Ken Griffin Janux Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$35.12 - $64.78 $793,712 - $1.46 Million	-22,600 Reduced 43.46%	29,400 $1.23 Million
Q1 2024 May 15, 2024	BUY	$7.93 - $49.75 $406,809 - $2.55 Million	51,300 Added 7328.57%	52,000 $1.96 Million
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $1,755 - $3,510	300 Added 75.0%	700 $7,000
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $9,560 - $14,000	-1,000 Reduced 71.43%	400 $4,000
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $7,756 - $11,144	-700 Reduced 33.33%	1,400 $16,000
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $5,625 - $11,105	500 Added 31.25%	2,100 $25,000
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $17,760 - $29,216	1,600 New	1,600 $21,000

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.